L left-sided mCRC (n=8, confirmed and unconfirmed)– 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed ...
TipRanks on MSN
Incyte’s INCA33890: A Promising Step in Cancer Treatment
Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is currently conducting a Phase 1 clinical study titled A ...
Merus (MRUS) announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody ...
Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, ...
Cardiff Oncology (CRDF) is a speculative buy with potential blockbuster gains ahead of its 2026 data readout. Read here for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback